Eli Lilly Stocks Rise as China Approves Orforglipron Weight-Loss Pill

Lilly's oral obesity drug wins Chinese approval, setting up a fight with Novo Nordisk, Pfizer and Innovent in a vast market. Related Stocks: LLY ,

Read original article